AC Immune SA (ACIU)
2.85
-0.07
(-2.40%)
USD |
NASDAQ |
Aug 26, 12:06
AC Immune Net Income (Quarterly) : 2.371M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.371M |
| March 31, 2026 | -18.89M |
| December 31, 2025 | -17.98M |
| September 30, 2025 | -19.82M |
| June 30, 2025 | -25.63M |
| March 31, 2025 | -21.17M |
| December 31, 2024 | -18.00M |
| September 30, 2024 | 6.351M |
| June 30, 2024 | -25.16M |
| March 31, 2024 | -20.43M |
| December 31, 2023 | -5.347M |
| September 30, 2023 | -17.14M |
| June 30, 2023 | -18.73M |
| March 31, 2023 | -18.93M |
| December 31, 2022 | -19.45M |
| September 30, 2022 | -13.98M |
| June 30, 2022 | -20.35M |
| March 31, 2022 | -20.40M |
| December 31, 2021 | -23.08M |
| September 30, 2021 | -17.34M |
| June 30, 2021 | -20.95M |
| March 31, 2021 | -18.47M |
| Date | Value |
|---|---|
| December 31, 2020 | -21.57M |
| September 30, 2020 | -20.65M |
| June 30, 2020 | -16.33M |
| March 31, 2020 | -7.940M |
| December 31, 2019 | -19.65M |
| September 30, 2019 | 18.47M |
| June 30, 2019 | -16.85M |
| March 31, 2019 | 63.77M |
| December 31, 2018 | -14.74M |
| September 30, 2018 | -13.74M |
| June 30, 2018 | -11.31M |
| March 31, 2018 | -12.25M |
| December 31, 2017 | 4.219M |
| September 30, 2017 | -9.133M |
| June 30, 2017 | -12.53M |
| March 31, 2017 | -9.423M |
| December 31, 2016 | -4.760M |
| September 30, 2016 | -9.330M |
| June 30, 2016 | 13.34M |
| March 31, 2016 | -6.213M |
| December 31, 2015 | -4.635M |
| September 30, 2015 | 20.84M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 237.40M |
| CRISPR Therapeutics AG | -91.15M |
| Idorsia Ltd. | -135.44M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 19.12M |
| Total Expenses (Quarterly) | 16.75M |
| EPS Diluted (Quarterly) | 0.026 |
| Enterprise Value | 177.68M |
| Profit Margin (Quarterly) | 12.40% |
| Earnings Yield | -19.51% |
| Normalized Earnings Yield | -19.37 |